Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B

Details

The acquisition, unanimously approved by the boards of both companies, is expected to close in Q3 2026, pending shareholder approval and other conditions. The deal values Crinetics at $85 per share and is expected to accelerate Vertex's revenue growth and enhance its long-term earnings profile. Crinetics' portfolio includes PALSONIFY, an FDA and EMA approved once-daily oral therapy for acromegaly, and atumelnant, a once-daily oral ACTH receptor antagonist for congenital adrenal hyperplasia, among other potential opportunities.

Items reported

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.